1. Home
  2. AIOS vs VERU Comparison

AIOS vs VERU Comparison

Compare AIOS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIOS

AIOS Tech Inc. Class A Common Shares

N/A

Current Price

$9.03

Market Cap

39.5M

Sector

Industrials

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.21

Market Cap

41.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIOS
VERU
Founded
2005
1971
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
41.9M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
AIOS
VERU
Price
$9.03
$2.21
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
16.1K
★ 204.9K
Earning Date
09-21-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.39
$2.05
52 Week High
$33.87
$7.33

Technical Indicators

Market Signals
Indicator
AIOS
VERU
Relative Strength Index (RSI) 30.87 39.50
Support Level $0.43 $2.11
Resistance Level $16.33 $2.68
Average True Range (ATR) 0.68 0.14
MACD -0.08 -0.01
Stochastic Oscillator 0.00 17.44

Price Performance

Historical Comparison
AIOS
VERU

About AIOS AIOS Tech Inc. Class A Common Shares

AIOS Tech Inc is a provider of artificial intelligence and technology-driven professional services. The Company is focused on delivering information technology solutions, data services, and artificial intelligence-powered offerings to a diverse commercial client base. Its core businesses include digital transformation services, tailored IT solutions for the financial sector, enterprise data solutions, and the development of AI platforms and infrastructure to drive efficiency and growth for clients across multiple industries.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: